Epigenetic regimen of chidamide, decitabine, and thymalfasin investigated for AML relapse post-transplant

Acute myeloid leukemia (AML) remains an aggressive hematologic malignancy, with allogeneic hematopoietic stem cell transplantation (allo-SCT) serving as a critical curative option. However, early-stage relapse post-transplant is a devastating complication, often driven by immune evasion mechanisms that allow residual leukemia cells to escape host immune surveillance. A key aspect of effective anti-tumor immunity involves the balanced differentiation and function of T helper cell subsets, particularly the Th1/Th17 lineage ratio. Dysregulation of this balance can contribute to immune tolerance and disease progression. Current standard-of-care options for AML relapse post-allo-SCT are often insufficient, necessitating novel therapeutic strategies that can restore robust anti-leukemic immune responses.

Researchers investigated the safety and efficacy of a novel epigenetic regimen in 24 non-APL acute myeloid leukemia (AML) patients. All participants had experienced early-stage relapse following allogeneic hematopoietic stem cell transplantation (allo-SCT). The intervention consisted of a simultaneous administration of the epigenetic drugs chidamide and decitabine, combined with the immunomodulator thymalfasin. The study aimed to assess the overall safety profile and clinical efficacy of this multi-modal approach, particularly its potential to reverse immune evasion and promote a favorable Th1/Th17 lineage ratio, as hypothesized in the study's title.